ClinicalTrials.gg
RecruitingNCT00360646ILIADUpdated Apr 8, 2026

Drug-Induced Liver Injury (DILI) Network Retrospective

An observational study in Drug Induced Liver Injury, sponsored by Duke University. Recruiting at 6 sites in United States. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2026-04-08.

Sponsored by Duke University · Observational

How we know

From the registry’s dates

  • Started Sep 2004; still recruiting 22 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
400
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Chemical and Drug Induced Liver Injury with a site in United States — 2 open to participants now, 2 under way, none of them phase 3. Chemical and Drug Induced Liver Injury · United States.

Started
2004
the only one that year
Observational
3 of 13
1 open now
Registered
1st of 13
by date
Lead sponsor
1 of 13
Duke University

Among the 13 studies in Chemical and Drug Induced Liver Injury with a site in United States, this one is the only one that started in 2004, is one of 3 observational ones, and was the 1st registered.

Chemical and Drug Induced Liver Injury

81 studies on the registry are indexed under Chemical and Drug Induced Liver Injury; 21 are open to participants now.

Browse Chemical and Drug Induced Liver Injury studies →

Open to participants now

2 of the 13 studies in Chemical and Drug Induced Liver Injury with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Chemical and Drug Induced Liver Injury studies recruiting now, 7 (58%) set no upper age limit and 3 (25%) stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.

This study: 2 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Chemical and Drug Induced Liver Injury with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to establish retrospectively a nationwide registry of patients who have suffered drug-induced liver injury (DILI), and to collect, immortalize, and store serum, DNA, and lymphocytes from these patients. ILIAD will serve as a resource for subsequent mechanistic investigations into the basis of severe idiosyncratic DILI. The primary goal of the ILIAD protocol is to create: (a) a clinical database consisting of individuals who have experienced severe DILI and the relevant clinical data concerning the episode of DILI; and, (b) to create a bank of biological specimens obtained from these individuals. These biological specimens will be DNA, plasma, and immortalized lymphocytes. Immortalized lymphocytes will provide unlimited amounts of genomic DNA for study as well as living immune cells for phenotyping studies.

A secondary goal of the ILIAD protocol is to maintain a registry of cases in the ILIAD database so that they may be recontacted in the future. It is expected that this will facilitate additional studies exploring the mechanisms of DILI.

Read the detailed description

Drug-induced liver injury (DILI) is the single most common reason for regulatory actions concerning drugs, including failure to gain approval for marketing, removal from the market place, and restriction of prescribing indications. DILI is also a significant cause of morbidity and mortality in many patient populations. To stimulate and facilitate research into DILI, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) has recently established the Drug-Induced Liver Injury Network (DILIN). One of the initial projects to be conducted by the network is to retrospectively establish a nationwide registry of patients who have suffered severe idiosyncratic liver injury associated with any drugs (ILIAD) and HDS agents, and to collect, immortalize and store serum, DNA, and lymphocytes from these patients (hereafter referred to as the "ILIAD protocol"). This ILIAD protocol will serve as a resource for subsequent mechanistic investigations of the basis for susceptibility to severe idiosyncratic DILI.

The network will initially identify people who have developed DILI onset beyond 6 months of enrollment due to all drugs or HDS/CAM cases that did not meet the entrance criteria for the Prospective study.

The specific aims are as follows:

  1. Establish and maintain a clinical database of these people that contains relevant clinical data.
  2. Establish a bank of biological specimens (serum, DNA, and immortalized lymphocytes) prepared from cases and control in the clinical database.
  3. Maintain a registry including yearly updated contact information of the subjects enrolled in the clinical database so that it is possible to recontact these individuals at a later date to offer participation in studies which are not part of the current proposal.
03

Conditions studied

  • Drug Induced Liver Injury

Keywords

  • LIVER DIS
  • CHEM IND
  • Drugs
  • Drug induced liver injury
  • phenotype
  • cholestatic liver injury
  • hepatocellular liver injury
  • mixed liver injury
  • genotype
04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with liver injury ascribed to any drug or HDS/CAM agent which the DILI onset date occurred beyond six months from enrollment.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Screening Criteria

To be included in the ILIAD registry, the following criteria must be satisfied:

  • The treating gastroenterologist / hepatologist or health care professional must believe that the subject suffered drug-induced liver injury;
  • The subject must be alive and the date of onset of the qualifying DILI episode must have occurred on or after January 1, 1994;
  • Evidence of injury that is known or suspected to be related to consumption of a drug or HDS/CAM product
  • The subject is taking only one of these drugs or HDS agent(s) in the period leading up to the onset of the qualifying DILI episode;
  • Have DILI defined in terms of serum (AST), alanine aminotransferase (ALT), and alkaline phosphatase (Alk Phos).
  • Sufficient documentation of the event for the Causality Committee to make a determination.

Exclusion criteria

Exclusion Criteria:

Subjects will be excluded according to the following criteria:

  • are not willing to have medical information and blood samples taken;
  • are unable to adequately give to participate in the study including the blood draw for the genetic component;
  • age \< 2 years old at the time of study enrollment (due to blood volume requirements).
  • Have a competing cause of liver injury such as hepatic ischemia that the investigator felt to be the primary reason for the observed liver injury. Known, pre-existing hepatitis; primary biliary cirrhosis, primary sclerosing cholangitis, or other chronic biliary tract disease. Subjects are excluded due to acetaminophen hepatoxicity or liver transplant or bone marrow transplant prior to development of drug-CAM induced liver injury.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
400 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Subjects with liver injury
  • Subjects without liver injury
06

What researchers measure

Primary outcomes

  1. maintain a registry of cases in the ILIAD database

    maintain a registry of cases in the ILIAD database

    Time frame: July 2028

07

Study locations

6 of 6 sites recruiting
08

References and documents

Publications

  • Rochon J, Protiva P, Seeff LB, Fontana RJ, Liangpunsakul S, Watkins PB, Davern T, McHutchison JG; Drug-Induced Liver Injury Network (DILIN). Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury. Hepatology. 2008 Oct;48(4):1175-83. doi: 10.1002/hep.22442. PubMed 18798340 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2004 (actual). Primary completion is estimated for Jul 2028, 286 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2006
First posted
Aug 4, 2006
StartActual
Sep 2004
Primary completionEst.
Jul 31, 2028
CompletionEst.
Jul 31, 2028
Last update
Apr 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00360646
Lead sponsor
Duke University
Responsible party
Sponsor
First posted
Aug 4, 2006
Start date
Sep 2004
Primary completion
Jul 31, 2028 (estimated)
Completion
Jul 31, 2028 (estimated)
Last update
Apr 8, 2026

Study contacts

Eilene Pham
Contact
eilene.pham@duke.edu
919-660-7253
Matt Baum
Contact
matt.baum@duke.edu
919-668-0486
Huiman X. Barnhart, PhD
principal investigator · Duke University
Robert Fontana, MD
study chair · University of Michigan

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion